Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

The goal of the ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) is to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.  

This repository lists all clinical trials currently open, preparing to open, temporarily closed and recently closed to. The information provided should be used in conjunction with advice from health care professionals. 

A large number of trials that are run at our children’s cancer centres in Australia and New Zealand are international trials. Further information regarding the clinical trials listed is available on national/ international clinical trial registries such as ANZCTRclinicaltrials.gov and EU Clinical Trials Register.

Study Title Protocol ID Disease (Sub Disease) Diagnosis Stage Location Links Status Trial Open Date Trial Close Date Sites Study Type Phase Age Eligibility ANZCTR International registry ID's
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones AALL1631 Leukaemia (ALL) New diagnosis NSW / QLD / WA External
Registry ≫
Open 19/04/2018 Treatment Phase 3 1 year to 21 years at diagnosis NCT03007147
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) AALL1731 Leukaemia (ALL) New diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 15/10/2019 Treatment Phase 3 1 year to 31 Years NCT03914625
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy AALL1732 Leukaemia (ALL) New Diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 28/10/2019 Treatment Phase 3 1 Year to 24 Years NCT03959085
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome AAML1531 Leukaemia New diagnosis NSW / VIC / WA / NZ External
Registry ≫
Open 03/11/2015 Treatment Phase 3 90 days to 4 years NCT02521493
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) AAML18P1 Chronic Myeloid Leukaemia On treatment VIC / WA External
Registry ≫
Open 15/07/2019 Treatment Phase 2 up to 25 years NCT03817398
A phase I study of vinorelbine cyclophosphamide and Rapamycin for recurrent malignancies in children ACCT007 (Rap-CV) Malignancies Relapsed/refractory NSW / VIC / WA / SA / NZ External
Registry ≫
Open 09/08/2019 Treatment Phase 1 up to 21 Years ACTRN12613000423718
Application of innovative molecular profiling techniques to improve diagnosis of paediatric central nervous system tumours and develop an accredited Australasian molecular profiling service ACCT009 (AIM BRAIN PROject) Central Nervous System Tumours
New Diagnosis
Relapse
NSW / QLD / VIC / WA / SA / NZ / TAS External
Registry ≫
Open 27/03/2018 Diagnosis Not applicable up to 21 years ACTRN12618000006246
A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age ACNS1221 Medulloblastoma New diagnosis NSW External
Registry ≫
Open 22/04/2014 Treatment Phase 2 up to 47 Months NCT02017964
A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients ACNS1422 Medulloblastoma New diagnosis NSW / WA / SA External
Registry ≫
Open Treatment Phase 2 3 years to 22 years at the time of enrollment NCT02724579
A Phase 2 Study of Veliparib (ABT-888 IND# 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations ACNS1721 Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 31/10/2018 Treatment Phase 2 3 Years to 25 Years NCT03581292
Australian Cardio-Oncology Registry ACOR All tumour types Newly diagnosed NSW / QLD / VIC / WA / SA / TAS Open 01/09/2018 Registry Not applicable up t 35 Years
A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors ACT001-AU-002 Advanced brain tumour
Advanced solid tumour
Relapse/refractory NSW / QLD External
Registry ≫
Open 18/09/2019 Treatment Phase 1 1 Year to 21 Years ACTRN12618001934235
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors AGCT1531 Germ Cell Tumour New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 08/05/2017 Treatment Phase 3 Various depending on risk group & consult protocol NCT03067181
Paediatric hepatic malignancy international therapeutic trial (PHITT) AHEP1531 Hepatoblastoma
Hepatocellular carcinoma
New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 04/10/2018 Treatment Phase 2/3 up to 30 Years NCT03533582
Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy ALLELE (ATA129-EBV-302) EBV post transplant Refractory VIC / WA External
Registry ≫
Open 29/12/2017 Treatment Phase 3 no limits NCT03394365
Key Adverse Events After Childhood Cancer ALTE03N1 Childhood Malignant Neoplasm Previously treated QLD / WA / SA External
Registry ≫
Open 24/03/2004 Observational Not applicable up to 21 Years NCT00082745
Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer ALTE07C1 All Tumour Types
New diagnosis
Relapse/refractory
NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 15/09/2008 Psycho-social Not applicable 3 Years to 21 Years NCT00772200
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy ALTE11C2 Leukaemia
Lymphoma
Previously treated WA External
Registry ≫
Open 05/08/2013 Late Effects Not applicable no limits NCT01790152
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study ALTE15N2 Recurrent Neuroblastoma Relapse/refractory WA / NZ External
Registry ≫
Open 05/06/2017 Late Effects Not applicable 5 Years to 50 Years NCT03057626
Neuroblastoma Biology Studies ANBL00B1 Solid tumours (Neuroblastoma) New diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 06/11/2000 Biology Biology 5 Years to 50 Years NCT03057626
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma ANBL1232 Ganglioneuroblastoma
Neuroblastoma
Relapse/refractory NSW / QLD / WA / SA / NZ External
Registry ≫
Open 28/07/2014 Treatment Phase 3 up to 18 months NCT02176967
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma ANBL1821 Solid tumours (Neuroblastoma) Relapse/refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 28/05/2019 Treatment Phase 2 1 Year and older NCT03794349
Pilot Study of Dinutuximab Sargramostim (GM-CSF) and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma ANBL19P1 Neuroblastoma New Diagnosis WA External
Registry ≫
Open 30/11/2020 Treatment Pilot up to 30 Years NCT04385277
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours ANZUP 1302 Germ Cell Tumour New diagnosis QLD / NZ External
Registry ≫
Open 01/02/2014 Treatment Phase 3 11 Years to 45 Years NCT02582697
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study APEC14B1 All Tumour Types NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 26/10/2015 Registry Not applicable up to 25 years NCT02402244
Renal Tumors Classification Biology and Banking Study AREN03B2 Renal tumours Newly diagnosed NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 27/06/2007 Observational Not applicable up to 29 Years NCT00898365
A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma ARRAY-162-115 Solid tumours New diagnosis
Relapse/refractory
NSW / VIC External
Registry ≫
Open 13/08/2020 Treatment Phase 1 12 Years to 17 Years NCT03878719
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) ARST1431 Rhabdomyosarcoma New diagnosis NSW / QLD / WA / NZ External
Registry ≫
Open 09/12/2016 Treatment Phase 3 under 40 years of age NCT02567435
A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors ARST1921 Desmoid-Type Fibromatosis New Diagnosis
Relapse
WA External
Registry ≫
Open 21/09/2020 Treatment Phase 2 12 Months to 18 Years NCT04195399
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia ASSET Leukaemia Previously treated NSW / VIC / WA / SA / NZ External
Registry ≫
Open 20/08/2015 Registry Not applicable up to 18 years
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban B0661037 Venous Thromboembolism New Diagnosis
Relapse/Refractory
NSW External
Registry ≫
Open 02/08/2018 Treatment Phase 4 3 Months to 17 Years NCT02464969
Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study Bu4Day-PK-2016 Haematopoietic Stem Cell Transplant Newly diagnosed
Relapsed/refractory
NSW / QLD / WA External
Registry ≫
Open 29/05/2017 Observational Pilot up to 18 years ACTRN12617000227392
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) CA045020 / NKTR-214 All tumour types Relapsed/refractory WA External
Registry ≫
Open 15/04/2021 Treatment Phase 1/2 up to 30 years NCT04730349
A Phase 1 Study of CD19 Specific Chimeric Antigen Receptor T-cell for Therapy of persistent and Relapsed B-cell leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study) CARTELL Leukaemia Relapse/refractory NSW External
Registry ≫
Open 19/11/2017 Treatment Phase 1 no limits ACTRN12617001579381
Developing genetically modified TCells for the treatment of paediatric solid tumours CARTpaedST Solid tumours New diagnosis Open 08/04/2018 Treatment Phase 1 up to 18 years
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy CCTL019A2205B Previously treated VIC External
Registry ≫
Open 02/11/2015 Observational Not applicable Child, Adult, Older Adult NCT02445222
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia CFZ2008 / 20140106 Acute Lymphoblastic Leukaemia (ALL) Relapse/refractory NSW / QLD / VIC External
Registry ≫
Open 10/09/2015 Treatment Phase 1/2 1 Month to 21 Years NCT02303821
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation CINC424F12201 / REACH4 Acute Graft Versus Host Disease New Diagnosis
Relapse/Refractory
NSW External
Registry ≫
Open 23/08/2018 Treatment Phase 1/2 up to 17 years NCT03491215
A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion CONNECT1903 Brain and Spinal Tumours (High Grade Gliomas) New diagnosis WA External
Registry ≫
Open 08/04/2021 Treatment Pilot up to 21 years NCT04655404
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma DAY101-001 (FIREFLY) Low-grade Glioma Relapse/refractory NSW / WA External
Registry ≫
Open 17/03/2021 Treatment Phase 2 6 Months to 25 Years NCT04775485
A Phase 1 Open-Label Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors Lymphoma and Malignant Brain Tumors DCL-17-001 Various Relapsed
Refractory
Recurrent
NSW External
Registry ≫
Open 30/04/2019 Treatment Phase 1 2 Years to 25 Years NCT03478462
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository DIPG Diffuse Intrinsic Pontine Glioma WA External
Registry ≫
Open 30/06/2012 Registry Not applicable Child, Adult, Older Adult NCT03101813
A Multicenter Open-label Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma E7080-G000-230 (OLIE) Solid tumours (Osteosarcoma) Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 23/03/2020 Treatment Phase 2 2 Years to 25 Years NCT04154189
A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) ECREST Solid tumours
CNS tumours
Relapse/refractory NSW / QLD External
Registry ≫
Open 08/02/2016 Treatment Phase 1 2 Years to 21 Years NCT02687386
A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A EFC16295 Hemophilia A Recurrent/ refractory QLD External
Registry ≫
Open 19/02/2021 Treatment Phase 3 up to 12 years NCT04759131
A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma EZH102 Solid tumours Relapse/ refractory
QLD External
Registry ≫
Open 27/05/2016 Treatment Phase 1 6 months to 21 years NCT02601937
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue HeadStart4 Medulloblastoma
PNET
Newly diagnosed NZ External
Registry ≫
Open 01/09/2015 Treatment Phase 4 up to 10 Years NCT02875314
Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies HoTRODS Diffuse Pontine Glioma
Diffuse Midline Glioma
High grade glioma
New Diagnosis
Relapse
NSW / WA External
Registry ≫
Open 17/07/2012 Observational Not applicable no limits ACTRN12612001183875
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies INFORM2 NivEnt CNS Tumour
Solid Tumour
Recurrent/ refractory
NSW / VIC / WA External
Registry ≫
Open 26/07/2019 Treatment Phase 1/2 6 Years to 21 Years NCT03838042
A clinical trial of donor-derived WT1 specific T cells for prevention of relapse in combination with multiple pathogen specific T cells for prevention of infection in patients undergoing allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia INTACT-TAA Leukaemia (AML)
Relapse/ refractory
NSW External
Registry ≫
Open 01/03/2017 Treatment Phase 1 1 Year to 70 Years NCT02895412
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma J10-MC-JZHD Solid tumours Relapsed/ refractory NSW / WA External
Registry ≫
Open 11/06/2020 Treatment Phase 1 2 years to 21 years NCT04106219
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis LCH-IV Langerhans Cell Histiocytosis New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 14/04/2014 Treatment Phase 3 up to 18 years NCT02205762
European Low and Intermediate Risk Neuroblastoma – A SIOPEN Study LINES Solid tumours(Neuroblastoma) New diagnosis NSW / VIC / WA External
Registry ≫
Open 31/05/2019 Treatment Phase 3 90 days to 18 Years NCT01728155
A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers LOXO-EXT-17005 Solid tumours Relapse/ refractory
NSW / VIC External
Registry ≫
Open 11/07/2018 Treatment Phase 1/2 1 Month and older NCT03215511
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours LOXO-RET-18036 Brain and Spinal Tumours Relapse/ refractory NSW / VIC External
Registry ≫
Open 01/07/2019 Treatment Phase 1/2 6 months to 21 years NCT03899792
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors LOXO-TRK-15003 Solid tumours New diagnosis
Relapse/ refractory
NSW / VIC External
Registry ≫
Open 11/09/2017 Treatment Phase 1/2 up to 21 years NCT02637687
A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies M13-833 Leukaemia (ALL/AML) Relapse/ refractory NSW / QLD / VIC / SA External
Registry ≫
Open 17/08/2017 Treatment Phase 1 up to 25 years NCT03236857
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma MK-3475-051 Solid Tumour
Lymphoma
Relapse/ refractory NSW / QLD External
Registry ≫
Open 04/04/2016 Treatment Phase 1/2 6 months to 17 years NCT02332668
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT MK-8228-030 Cytomegalovirus (CMV) Infection New Diagnosis
Relapse/Refractory
NSW / QLD / VIC External
Registry ≫
Open 08/08/2019 Treatment Phase 2 up to 17 years NCT03940586
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI) NB SCI Registry Neuroblastoma NSW / QLD / VIC / WA / SA / TAS External
Registry ≫
Open 01/04/2015 Registry Not applicable up to 18 Years NCT02559804
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma OZM-063 (LGG Avastin) Brain and Spinal Tumours(Low Grade Gliomas) New diagnosis
Relapse/ refractory
NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 29/05/2018 Treatment Phase 2 6 months to 18 years old NCT02840409
Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers OZM-075 (Hypermutant Cancer) All Tumour Types Relapse/ refractory
QLD / VIC / SA External
Registry ≫
Open 06/12/2019 Treatment Pilot 12 months to 25 years NCT02992964
Phase I/Ib trial of combined 5’azacitidine and carboplatin for recurrent/refractory pediatric brain and solid tumours OZM-077 (COZMOS) Brain and Spinal Tumours (Ependymoma) Relapse/ refractory NSW / QLD / VIC / WA / SA External
Registry ≫
Open 01/09/2019 Treatment Phase 1 1 year to 18 years NCT03206021
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients P3505 Haematological diseases New Diagnosis
Relapse/Refractory
QLD External
Registry ≫
Open 17/06/2020 Supportive Care Phase 1 3 months to 18 years ACTRN12620000141943
TCR a+ß+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients Pablo Bone marrow transplant New Diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 06/09/2018 Treatment Phase 2 up to 18 years ACTRN12617001174370
Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) PCYC-1146-IM Chronic Graft Versus Host Disease New Diagnosis
Relapse/Refractory
NSW / VIC External
Registry ≫
Open 22/01/2019 Treatment Phase 1/2 Part A – 1 to 12 years Part B – 1 to 22 years NCT03790332
A Randomized Double-Blinded Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG) PNOC 0019 Brain and Spinal Tumours (High Grade Gliomas) Relapsed/ refractory NSW / WA External
Registry ≫
Open 01/03/2021 Treatment Pilot 6 Months to 22 Years NCT04323046
A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation Ponatinib-1501 /AALL1922 Leukaemia (ALL) Relapse/ refractory VIC External
Registry ≫
Open 21/02/2021 Treatment Phase 1/2 1 Year to 21 Years NCT04501614
International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions PPB DICER Pleuropulmonary Blastoma WA External
Registry ≫
Open 06/12/2015 Registry Not applicable Child, Adult, Older Adult NCT03382158
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients PREDICT All tumour types Newly diagnosed NSW External
Registry ≫
Open 08/03/2021 Observational Not applicable up to 21 years NCT04903782
PRecISion Medicine for Children with Cancer PRISM All Tumour Types New Diagnosis
Relapse/ Refractory
NSW / QLD / VIC / WA / SA External
Registry ≫
Open 05/09/2017 Biology Biology up to 21 years NCT03336931
Ph3 Randomized Double-Blind Placebo-Controlled Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) PRN1008-018 Immune Thrombocytopenia Recurrent/ refractory QLD External
Registry ≫
Open 14/12/2020 Treatment Phase 3 12 Years and older NCT04562766
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation R3ACT Fungal Invasive Fungal Disease Newly diagnosed
Relapsed/Refractory
NSW External
Registry ≫
Open 19/08/2019 Treatment Phase 1 1 Years to 80 Years ACTRN12618001540202
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma ReRAD Brain and Spinal Tumours Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 15/04/2017 Treatment Phase 2 up to 17 years NCT03126266
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma RG_13-277 (rEECur) Solid tumours (Ewings sarcoma) Relapse/ refractory NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 03/04/2018 Treatment Phase 2/3 4 years to 50 years ACTRN12618001825246
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy RG_14-088 (MyeChild-01) Leukaemia (AML) New diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 04/07/2018 Treatment Phase 3 up to 18 years NCT02724163
A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood RG_16-040 (PARC) All Tumour Types (Other)
Relapse/ refractory
NSW / QLD / VIC / WA / SA External
Registry ≫
Open 29/11/2019 Treatment Phase 1/2 1 year to 25 years NCT03455140
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma RG_17-427 (FAR-RMS) Rhabdomyosarcoma Relapsed/ refractory VIC / NZ External
Registry ≫
Open 17/09/2020 Treatment Phase 1 no limits NCT04625907
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors SJ ELiOT Brain and Spinal Tumours (Medulloblastoma/ PNET) Relapse/ refractory NSW / QLD / VIC / WA External
Registry ≫
Open 02/10/2019 Treatment Phase 1 1 year to 25 years NCT04023669
A Clinical and Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma SJMB12 Brain and Spinal Tumours (Medulloblastoma/PNET) New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 12/03/2014 Treatment Phase 3 3 Years to 39 Years NCT01878617
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group) Study10 Lymphoblastic leukaemia Newly diagnosed NSW External
Registry ≫
Open 15/07/2018 Treatment Phase 3 up to 17 Years NCT03643276
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) T2017-002 Leukaemia (ALL) Relapsed/ refractory NSW External
Registry ≫
Open 12/02/2019 Treatment Phase 1/2 1 Year to 21 Years NCT03817320
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial TAPISTRY All tumour types Relapsed/ refractory NSW External
Registry ≫
Open 18/01/2021 Treatment Phase 2 no limits NCT04589845
A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas TiNT Solid tumours (Other Solid Tumour) Relapsed/ refractory NSW / QLD / VIC / WA / NZ / TAS External
Registry ≫
Open 01/03/2021 Treatment Phase 2 3 Months to 25 Years ACTRN12620001229965
A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations TPX-0005-07 Solid tumours Relapsed/ refractory NSW / QLD / WA External
Registry ≫
Open 20/03/2020 Treatment Phase 1/2 up to 25 years NCT04094610